anaplastic lymphoma kinase
Showing 1 - 25 of 7,571
Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)
Not yet recruiting
- Lung Cancer
- Non-small Cell Lung Cancer
- Lorlatinib
- +2 more
- (no location specified)
Jul 7, 2023
NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)
Not yet recruiting
- NSCLC Stage IV
- ALK Fusion Protein Expression
- Peptide vaccine
- (no location specified)
Jul 21, 2023
free Survival and Evaluate Participant Experience for Metastatic
Active, not recruiting
- Anaplastic Lymphoma Kinase-positive
- Carcinoma Non-small-cell Lung
- Brigatinib
- +4 more
-
Maynard, MassachusettsEmpiraMed, Inc.
Feb 28, 2022
NSCLC Trial in Tianjin (Ensartinib, Placebo)
Recruiting
- Non-small Cell Lung Cancer
- Ensartinib
- Placebo
-
Tianjin, ChinaTianJin Medical University Cancer Institute & Hospital
Jul 13, 2022
NSCLC Trial in Shanghai (WX-0593)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Shanghai, ChinaShanghai Jiao Tong University Chest Hospital
Mar 24, 2023
Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer
Active, not recruiting
- Non-Small-Cell Lung Carcinoma
-
New York, New YorkPfizer Inc
Apr 12, 2022
Anaplastic Lymphoma Kinase Gene Translocation, NSCLC Trial in Boston
Recruiting
- Anaplastic Lymphoma Kinase Gene Translocation
- Non-Small Cell Lung Cancer
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Jan 14, 2022
Usage of Brigatinib in Treatment of Adult Approved Indications
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Anaplastic Lymphoma Kinase
- No Intervention
-
Busan, Korea, Republic ofPusan National University Hospital
Oct 19, 2022
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
-
Beijing, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022
Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)
Completed
- Lymphoma, Large-Cell, Anaplastic
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
Jul 26, 2021
NSCLC Trial (Zimberelimab, Domvanalimab, Pembrolizumab)
Not yet recruiting
- Non-small Cell Lung Cancer
- Zimberelimab
- +7 more
- (no location specified)
Aug 12, 2022
Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Recruiting
- Relapsed Plasmablastic Lymphoma
- +2 more
- Belantamab Mafodotin
-
Boston, Massachusetts
- +2 more
Sep 20, 2021
NSCLC Trial in Chang Chun (XZP-3621, Crizotinib)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Chang Chun, Ji Lin, ChinaJilin Province Cancer Hospital
Jan 10, 2022
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) Trial in Sunto-gun, Koto, Fukuoka (LDK378)
Completed
- Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
-
Sunto-gun, Shizuoka, Japan
- +2 more
Dec 16, 2020
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)
Recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Orange, California
- +13 more
Jan 31, 2023
ALK or ROS1-positive NSCLC Trial in China (Crizotinib)
Active, not recruiting
- ALK or ROS1-positive NSCLC
-
Fuzhou, Fujian, China
- +9 more
Aug 30, 2022
Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
Active, not recruiting
- ALK-Positive Anaplastic Large Cell Lymphoma
- RNAseq
-
Toulouse, FranceIUCT-Oncopole University Hospital
Jul 3, 2023
NSCLC Trial (Brigatinib)
Completed
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
Feb 18, 2021
NSCLC (NSCLC) Trial in Boston (Lorlatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
-
Boston, MassachusettsMassachusetts general Hospital
Mar 7, 2021
NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)
Completed
- Non-Small Cell Lung Cancer ALK-positive
- +4 more
- PF-02341066
- +2 more
-
Orange, California
- +28 more
Feb 15, 2022